Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference

被引：166

作者：

Kirchhof, Paulus ^{[1
,2
]}

Lip, Gregory Y. H. ^{[3
]}

Van Gelder, Isabelle C. ^{[4
]}

Bax, Jeroen ^{[5
]}

Hylek, Elaine ^{[6
]}

Kaab, Stefan ^{[7
]}

Schotten, Ulrich ^{[8
]}

Wegscheider, Karl ^{[9
]}

Boriani, Giuseppe ^{[10
]}

Brandes, Axel ^{[11
]}

Ezekowitz, Michael ^{[12
]}

Diener, Hans ^{[13
]}

Haegeli, Laurent ^{[14
]}

Heidbuchel, Hein ^{[15
]}

Lane, Deirdre ^{[3
]}

Mont, Luis ^{[16
]}

Willems, Stephan ^{[9
]}

Dorian, Paul ^{[17
]}

Aunes-Jansson, Maria ^{[18
]}

Blomstrom-Lundqvist, Carina ^{[19
]}

Borentain, Maria ^{[20
]}

Breitenstein, Stefanie ^{[21
]}

Brueckmann, Martina ^{[22
]}

Cater, Nilo ^{[23
]}

Clemens, Andreas ^{[22
]}

Dobrev, Dobromir ^{[24
]}

Dubner, Sergio ^{[25
]}

Edvardsson, Nils G. ^{[18
]}

Friberg, Leif ^{[26
]}

Goette, Andreas ^{[27
]}

Gulizia, Michele ^{[28
]}

Hatala, Robert ^{[29
]}

Horwood, Jenny ^{[30
]}

Szumowski, Lukas ^{[31
]}

Kappenberger, Lukas ^{[32
]}

Kautzner, Josef ^{[33
]}

Leute, Angelika ^{[1
,2
]}

Lobban, Trudie ^{[34
]}

Meyer, Ralf ^{[35
]}

Millerhagen, Jay ^{[36
]}

Morgan, John ^{[37
]}

Muenzel, Felix ^{[38
]}

Nabauer, Michael ^{[7
]}

Baertels, Christoph ^{[21
]}

Oeff, Michael ^{[39
]}

Paar, Dieter ^{[40
]}

Polifka, Juergen ^{[41
]}

Ravens, Ursula ^{[42
]}

Rosin, Ludger ^{[40
]}

Stegink, W. ^{[43
]}

机构：

[1] Univ Hosp Munster, Munster, Germany

[2] AFNET, Hamburg, Germany

[3] Univ Birmingham, Birmingham, W Midlands, England

[4] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands

[5] Leiden Univ, Leiden, Netherlands

[6] Boston Univ, Sch Med, Boston, MA 02118 USA

[7] Univ Munich, Munich, Germany

[8] Maastricht Univ, Maastricht, Netherlands

[9] Univ Hamburg, Hamburg, Germany

[10] Univ Bologna, Bologna, Italy

[11] Odense Univ Hosp, DK-5000 Odense, Denmark

[12] Jefferson Med Coll, Wynnewood, PA USA

[13] Univ Essen Gesamthsch, Essen, Germany

[14] Univ Zurich, Zurich, Switzerland

[15] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[16] Univ Barcelona, Barcelona, Spain

[17] Univ Toronto, Toronto, ON, Canada

[18] Astra Zeneca Res & Dev, Molndal, Sweden

[19] Uppsala Univ, Uppsala, Sweden

[20] Bristol Myers Squibb Europe, Rueil Malmaison, France

[21] Bayer Vital GmbH, Leverkusen, Germany

[22] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany

[23] Pfizer Inc, New York, NY USA

[24] Heidelberg Univ, Med Fac Mannheim, D-6800 Mannheim, Germany

[25] Clin Suizo Argentina, Buenos Aires, DF, Argentina

[26] Soder Sjukhuset, Karolinska Inst, Stockholm, Sweden

[27] St Vincenz Hosp Paderborn, Paderborn, Germany

[28] Garibaldi Nesima Hosp, Catania, Italy

[29] Slovak Cardiovasc Inst, Bratislava, Slovakia

[30] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England

[31] Inst Cardiol, Warsaw, Poland

[32] Univ Lausanne, Lausanne, Switzerland

[33] Inst Clin & Expt Med, Prague, Czech Republic

[34] Atrial Fibrillat Assoc Int, Bristol, Avon, England

[35] Medtron Int Trading Sarl, Tolochenaz, Switzerland

[36] St Jude Med, St Paul, MN USA

[37] Univ Southhampton, Southampton, Hants, England

[38] Daiichi Sankyo Europe GmbH, Munich, Germany

[39] Stadt Klinikum Brandenburg, Brandenburg, Germany

[40] Sanofi Aventis Deutschland GmbH, Berlin, Germany

[41] MSD Reg Business Support Ctr GmbH, Haar, Germany

[42] Tech Univ Dresden, Dresden, Germany

[43] AGA Med Corp, Milan, Italy

[44] Univ Hosp Heraklion, Iraklion, Greece

[45] St Georges Univ, London, England

来源：

EUROPACE | 2012年 / 14卷 / 01期

关键词：

atrial fibrillation; management; outcomes; antithrombotic therapy; rate control; rhythm control; risk factors; early therapy; C-REACTIVE PROTEIN; RADIOFREQUENCY CATHETER ABLATION; GLOMERULAR-FILTRATION-RATE; CARDIOLOGY WORKING GROUP; LONG-QT SYNDROME; CARDIOVASCULAR INTERVENTIONS EAPCI; VENTRICULAR SYSTOLIC DYSFUNCTION; LOBAR INTRACEREBRAL HEMORRHAGE; CEREBRAL AMYLOID ANGIOPATHY; STERILE PERICARDITIS MODEL;

D O I：

10.1093/europace/eur241

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

While management of atrial fibrillation (AF) patients is improved by guideline-conform application of anticoagulant therapy, rate control, rhythm control, and therapy of accompanying heart disease, the morbidity and mortality associated with AF remain unacceptably high. This paper describes the proceedings of the 3rd Atrial Fibrillation NETwork (AFNET)/European Heart Rhythm Association (EHRA) consensus conference that convened over 60 scientists and representatives from industry to jointly discuss emerging therapeutic and diagnostic improvements to achieve better management of AF patients. The paper covers four chapters: (i) risk factors and risk markers for AF; (ii) pathophysiological classification of AF; (iii) relevance of monitored AF duration for AF-related outcomes; and (iv) perspectives and needs for implementing better antithrombotic therapy. Relevant published literature for each section is covered, and suggestions for the improvement of management in each area are put forward. Combined, the propositions formulate a perspective to implement comprehensive management in AF.

引用

页码：8 / 27

页数：20

共 227 条

[1] Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis [J].